Depomed Slapped By Shareholder Discontent

After a grueling battle to fight off unwanted acquirer Horizon Pharma last year, Depomed finds itself in another precarious position. The pain drug maker is now facing a battle with an activist investor that says it's shirking its fiduciary duties.

Starboard Value LP, which holds 6.8% of the company as of April 8, said in a filing with the US...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category